Thema: US4622601007
IOVA, US4622601007
trading-7181177_1280.jpg - Foto: THN
Iovance Biotherapeutics stock narrows lung cancer trial strategy
Iovance Biotherapeutics stock faces a narrower lung-cancer strategy after updated lifileucel data. Enrollment in a biomarker-selected cohort is due in November.
ad-hoc-news.de, heute 20:16 Uhr
IOVA, US4622601007
Moomoo reports USD 15.75 target for Iovance Biotherapeutics ...
Moomoo counted 8 analyst ratings on October 23, 2026, all marked Buy. Iovance Biotherapeutics stock costs EUR 12.57 on October 24, 2026.
ad-hoc-news.de, 24.10.26 19:31 Uhr
IOVA, US4622601007
Iovance Biotherapeutics stock: At Lang & Schwarz Iovance ...
Revenue exceeded estimates 13.07 percent. Iovance Biotherapeutics stock costs EUR 12.33 on October 22, 2026, down 7.15 percent versus the Frankfurt close.
ad-hoc-news.de, 22.10.26 19:06 Uhr
IOVA, US4622601007
Jefferies keeps USD 20 target for Iovance Biotherapeutics ...
Second-quarter 2026 revenue reached USD 99.31 million. Iovance Biotherapeutics stock costs EUR 13.21 on October 20, 2026.
ad-hoc-news.de, 20.10.26 21:21 Uhr
IOVA, US4622601007
Barclays lifts target for Iovance Biotherapeutics stock ...
Analysts average USD 13.20 across 13 firms on October 14, 2026. Iovance Biotherapeutics stock costs EUR 12.86 on October 15, 2026 at 10:20 p.m. CEST.
ad-hoc-news.de, 15.10.26 20:31 Uhr
IOVA, US4622601007
Iovance raised revenue guidance. Iovance Biotherapeutics ...
Outlook is USD 410 million to USD 420 million. Iovance Biotherapeutics stock costs EUR 11.89 on October 8, 2026, up 2.94 percent from EUR 11.55.
ad-hoc-news.de, 08.10.26 21:19 Uhr
Iovance, Biotherapeutics
Iovance Biotherapeutics: A Rollercoaster Ride for Investors ...
